Status
Conditions
About
This prospective, single-center observational study evaluates the clinical utility of intraoperative sympathetic nerve width measurement during thoracoscopic sympathectomy (ETS) for palmar/craniofacial hyperhidrosis (PH/CH) and facial blushing (FF). The study aims to correlate nerve width-measured using a novel Rapid Intraoperative Sympathetic Nerve Width System (RMSNW-OS) (±0.2mm precision)-with surgical outcomes, compensatory sweating rates, patient satisfaction, and 12-month efficacy.
Approximately 1,000 patients (aged 18-55) will undergo standardized ETS at Shanghai First People's Hospital (2025-2029). Objective metrics include thermographic (palmar/forehead temperature), hemodynamic (HR/BP), biochemical (catecholamines), and Doppler flow measurements. Patient-reported outcomes use diagnosis-specific binary questionnaires and the Hyperhidrosis Disease Severity Scale (HDSS).
Statistical analysis will determine if nerve width predicts treatment response. Innovations include RMSNW-OS standardization and a multidimensional assessment framework to optimize ETS precision and patient quality of life.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis : Confirmed autonomic nervous dysfunction (including palmar hyperhidrosis, craniofacial hyperhidrosis, or facial blushing).
Age : ≥18 years and ≤55 years.
Cardiopulmonary Function :
Normal preoperative chest CT scan and electrocardiogram (ECG).
Performance Status : ECOG score (see Attachment 1) of 0-1, indicating good clinical fitness and ability to perform daily activities independently.
Informed Consent : Patients and their families fully understand the study's purpose, procedures, risks, and potential benefits, voluntarily sign the Informed Consent Form, and agree to participate.
Exclusion criteria
Abnormal Preoperative ECG :
Severe arrhythmias:
Myocardial ischemia or infarction:
Severe pulmonary infections (e.g., lobar pneumonia, empyema) with symptoms like fever, cough, dyspnea. Surgery increases infection risk and may lead to atelectasis or respiratory failure.
Pneumothorax or tension pneumothorax:
Significant lung collapse causing dyspnea.
Tension pneumothorax requiring immediate chest tube drainage. 3) Pleural effusion (moderate/large volume): Causes dyspnea or mediastinal shift; surgery may worsen respiratory function.
Hyperthyroidism-induced facial blushing or generalized hyperhidrosis. 4. Anesthesia Contraindications : Allergy to anesthetics or high-risk conditions (severe pulmonary/cardiac dysfunction).
Cognitive/Psychiatric Impairment : Inability to provide informed consent or understand study risks.
Non-Compliance with Follow-up : Inability to adhere to postoperative visits.
Immunodeficiency Disorders : Severe immunodeficiency, AIDS, or organ transplant history.
Frailty/Advanced Age : Elderly patients with comorbidities or functional decline unfit for surgery.
Severe Organ Dysfunction : Cirrhosis, renal failure, or inability to tolerate surgery/recovery.
Active Infections : Under antibiotic treatment for pneumonia, tuberculosis, or bacterial infections.
Uncontrolled Diabetes : Poor glycemic control with complications (retinopathy, diabetic foot).
Concurrent Clinical Trials : Participation in other interventional studies affecting results.
Severe Malnutrition : Significant weight loss or nutritional deficiency increasing anesthesia/surgical risks.
Hematologic Disorders : Anemia, thrombocytopenia, or coagulopathies affecting hemostasis/recovery.
Severe Chronic Respiratory Failure : Long-term ventilator dependence or tracheostomy.
Loading...
Central trial contact
Qiongliang Liu, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal